Stability of Symptom Clusters in Patients With Lung Cancer Receiving Chemotherapy by Russell, Jacquelyn Ann
UCSF
UC San Francisco Electronic Theses and Dissertations
Title
Stability of Symptom Clusters in Patients With Lung Cancer Receiving Chemotherapy
Permalink
https://escholarship.org/uc/item/64v9t6nj
Author
Russell, Jacquelyn Ann
Publication Date
2019
Supplemental Material
https://escholarship.org/uc/item/64v9t6nj#supplemental
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
  
 
 
 
by 
 
 
 
 
Submitted in partial satisfaction of the requirements for degree of 
 
 
in 
 
 
 
in the 
 
GRADUATE DIVISION 
of the 
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
______________________________________________________________________________ 
       Chair 
 
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
Committee Members 



!%(%##
$$(( $%#$"#$$#$	%"&$" (
%"#
"#$
#'#
	(


#
 
 
 
 
 
 
Copyright 2019 
by 
Jacquelyn Russell 
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ABSTRACT 
Context: Patients with lung cancer who undergo chemotherapy (CTX) experience multiple 
concurrent symptoms. An evaluation of how these symptoms cluster together and how these 
symptom clusters change over time may provide insights into how to treat these multiple co-
occurring symptoms. 
 
Objectives: The purposes of this study, in a sample of lung cancer patients (n=145) who were 
receiving chemotherapy (CTX) were to evaluate for differences in the number and types of 
symptom clusters at three time points (i.e., before CTX, the week after CTX, and two weeks 
after CTX) using ratings of symptom occurrence and severity and to evaluate for changes in 
these symptom clusters over time. 
 
Methods: At each of the three assessments, a modified version of the Memorial Symptom 
Assessment Scale was used to assess the occurrence and severity of the 38 symptoms. 
Exploratory factor analyses were used to extract the symptom clusters. 
 
Results: Across the two symptom dimensions (i.e., occurrence and severity) and the three 
assessments, six distinct symptom clusters were identified. However, only three of these clusters 
were relatively stable across both dimensions and across time (i.e., lung cancer specific, 
psychological, nutritional). Two additional clusters varied by time but not by symptom 
dimension (i.e., epithelial/gastrointestinal, epithelial). A sickness behavior cluster was identified 
at each assessment with the exception of the week before CTX using the severity dimension. 
 Conclusion: These findings provide insights into the most common symptom clusters in patients 
undergoing CTX for lung cancer. The most common symptoms within each cluster appear to be 
relatively stable across the two dimensions, as well as across time.  
 
KEYWORDS: symptoms; symptom clusters; lung cancer; chemotherapy; exploratory factor 
analysis; symptom occurrence; symptom severity 
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INTRODUCTION 
Lung cancer is the most common cancer with 2.1 million cases worldwide (WHO, 2018). 
Patients diagnosed with lung cancer have an extremely high symptom burden throughout the 
course of their disease that negatively effects their physical and emotional well-being (Morrison, 
2017).  Given the high rates of multiple co-occurring symptoms associated with lung cancer, an 
evaluation of symptom clusters in these patients is highly relevant. A symptom cluster is defined 
as a group of three or more interrelated symptoms that have an influence on each other (Dodd, 
2001). In addition, symptoms within a cluster may share the same underlying mechanism (Dodd, 
2001). An increased understanding of symptom clusters associated with specific cancer, like lung 
cancer, will provide individualized direction for the assessment and management of symptoms in 
this vulnerable group of patients (Miaskowski et al., 2017). 
In one of the earliest studies of symptom clusters in patients with lung cancer (Sarna & 
Brecht, 1997), Sarna and Brecht hypothesized that the treatment of symptoms associated with 
chemotherapy (CTX) might improve if we understood the relationships among symptoms and 
symptom distress. In a sample of 60 women with advanced lung cancer, four groups of related 
symptoms were identified using factor analysis (i.e., emotional and physical suffering, 
gastrointestinal distress, respiratory distress, malaise). 
Since this initial publication in 1997, eight additional studies have evaluated for symptom 
clusters in patients with lung cancer. Four of these studies(Gift et al., 2004; Wang et al., 2006; 
Wang et al., 2008; Henoch et al., 2009)  were summarized, along with Sarna and Brecht’s paper, 
in a systematic review by Chen and colleagues (Chen et al., 2011), Three additional studies 
(Choi, 2016; Wang & Fu, 2014,Wong, 2017) including one from our research team (Wong, 
2017), were published following Chen et al.’s systematic review. Across these eight studies the 
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number of symptom clusters ranged from two to five. No common symptom cluster was found 
across all of the studies. However, an emotional/psychological symptom cluster was identified in 
five studies (Sarna & Bretcht, 1997; Henoch, 2009; Choi, 2016; Wang & Fu, 2014; Wong, 
2017), with sad being the most common symptom. In addition, a lung-cancer specific symptom 
cluster was found in four studies (Sarna et al., 1997; Henoch et al., 2009; Choi, 2016; 
Wong,2017) , with cough being the most common symptom. Finally, a gastrointestinal symptom 
cluster was identified in four studies (Sarna & Brecht, 1997; Wang et al, 2006; Wang et al, 2008; 
Wang & Fu, 2014), with nausea being the most common symptom. Comparisons of findings 
across these eight studies is difficult because different dimensions of the symptom experience 
were evaluated, different assessment tools were used, and different statistical procedures were 
utilized to evaluate the symptom clusters. Of note, except for our own study (Wong, 2017), none 
of the studies cited above evaluated for differences in symptom clusters using different 
dimensions of the symptom experience or evaluated for changes in symptom clusters over time.  
In our previous study of 145 patients receiving CTX for lung cancer, differences in the 
number and types of symptom clusters were evaluated using the occurrence and severity ratings 
of 38 symptoms from the Memorial Symptom Assessment Scale (MSAS). Across both 
dimensions, five relatively similar symptom clusters were identified (i.e., sickness behavior, 
lung-cancer specific, psychological, nutritional, epithelial). In addition, across the two symptom 
dimensions, the specific symptoms within each of the symptom clusters were relatively stable 
(Wong, 2017) 
Given that no studies of changes in symptom clusters over time in lung cancer patients 
were identified, this study expands on our previous research with this sample (Wong, 2017). The 
purposes of this study, in a sample of patients with lung cancer (n=145) who were receiving 
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CTX, were; 1) to evaluate for differences in the number and types of symptom clusters at three 
time points (I.e., T1, T2, T3) using ratings of occurrence and severity and 2) to evaluate for 
changes in these symptom clusters over time.  
MATERIALS AND METHODS 
Patients and Settings 
 This longitudinal analysis is part of a larger study, funded by the National Cancer 
Institute, that evaluated the symptom experience of oncology outpatients receiving CTX. (26) 
Details of the methods from the parent study are published elsewhere. (26, 27) In brief, the 
parent study enrolled adults who were ≥18 years of age with lung, breast, gastrointestinal, or 
gynecological cancer. Patients were recruited from two Comprehensive Cancer Centers, one 
Veterans Affairs hospital, and four community-based oncology programs. All patients had 
received CTX within the preceding four weeks and were scheduled to receive at least two 
additional cycles. Patients were required to read, write, and understand English and provided 
written informed consent. In the parent study, a total of 2,234 patients were approached and 
1,343 consented to participate (60.1% response rate). The major reason for refusal was being 
overwhelmed with cancer treatment. In the the current analysis, only patients with lung cancer 
were evaluated.  
Instruments 
The demographic questionnaire obtained information on age, gender, ethnicity, marital 
status, living arrangements, education, employment status, and income. Patients rated their 
functional status using the Karnofsky Performance Status (KPS) scale that ranged from 30 
(severely disabled) to 100 (normal). (28-30) The Self-Administered Comorbidity Questionnaire 
(SCQ) evaluated 13 common comorbidities. (31) Patients indicated if they had the condition, if 
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they received treatment for it, and if it limited their activities. SCQ scores could range from 0 to 
39. 
 A modified version of the MSAS (33) evaluated the occurrence and severity of 38 
symptoms commonly associated with cancer and its treatment. The following six symptoms were 
added to the original 32 MSAS symptoms: chest tightness, difficulty breathing, increased 
appetite, weight gain, abdominal cramps, and hot flashes. Patients indicated if they experienced 
each symptom in the past week (i.e., symptom occurrence). If yes, they rated its severity, 
frequency, and distress. Symptom severity was rated using a 4-point Likert scale (1 = slight, 
2 = moderate, 3 = severe, 4 = very severe). Only symptom occurrence and severity were included 
in the current analysis. The reliability and validity of the MSAS and its subscales are well 
established in studies of cancer patients. (33, 34) 
Study Procedures 
 The study was approved by the Institutional Review Board at the University of 
California, San Francisco and at each study site. Patients completed questionnaires in their 
homes a total of six times over two cycles of CTX. For this analysis, the first, second, and third 
assessments that obtained data in the week prior to the next cycle of CTX (T1), approximately 
one week after CTX administration (T2), and approximately two weeks after the administration 
of CTX (T3), were used to assess for symptom clusters. Medical records were reviewed for 
clinical information. 
Data Analysis 
Data were analyzed using Stata/SE version 14.1 (StataCorp, College Station, TX) and 
Mplus version 7.3 (Muthén & Muthén, Los Angeles, CA). Descriptive statistics and frequency 
distributions were calculated for the demographic and clinical characteristics.  
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Separate exploratory factor analyses (EFAs) were done to identify symptom clusters 
using dichotomous occurrence items and ordinal severity items. (32, 35) Factor analysis aims to 
identify whether correlations between a set of observed variables can be explained by latent, 
unobserved variables (i.e., factors).(36) In this study, we refer to these factors as symptom 
clusters. (2, 37). 
For the EFA, factor loadings (i.e., structure coefficients following rotation) of >0.40 were 
considered meaningful. (35, 38, 39) In addition, factors were considered to be adequately defined 
if at least two items (i.e., symptoms) had loadings of ≥0.40. (33) While it is common to require 
that each item load strongly on only one factor, we retained items that loaded on two factors (i.e., 
cross loaded) if they met our pre-specified criteria of ≥0.40. The cross loading of symptoms on 
more than one factor may be beneficial in the interpretation of potential causal mechanisms, 
especially when oblique rotation is employed. (40-43) To have sufficient variation and 
covariation in the data to perform the EFAs, only symptoms that were present in >20% but <80% 
of the patients were included in the analyses.  
 For the EFA using dichotomous occurrence items, tetrachoric correlations were used to 
create the matrix of associations. For the EFA using ordinal severity items, polychoric 
correlations were used to create the matrix of associations. (35, 44) The simple structure for the 
occurrence and severity EFAs were estimated using the method of unweighted least squares with 
geomin (i.e., oblique) rotation. The geomin rotation method was chosen to create the best fit for 
the model and improve the interpretability of each factor solution. (35, 37) The unweighted least 
squares estimator (ulsmv: unweighted least squares parameter estimates with standard errors and 
a mean and variance adjusted chi-square test using a full weight matrix (35, 42)) was selected in 
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order to achieve more reliable results because the scales for the MSAS items are dichotomous 
(i.e., occurrence) and ordinal (i.e., severity).  
 The EFA for severity was conducted using severity ratings that ranged from 0 (symptom 
not present) to 4 (very severe). A preliminary analysis was conducted using severity ratings that 
ranged from 1 (mild) to 4, omitting observations where the symptom was not present. However, 
the pairwise missingness (i.e., minimum covariance function across all item pairs) was over 90% 
for many pairs and the estimation failed. Therefore, the EFAs for the severity ratings were 
estimated including zeros.  
 Factor solutions were estimated for two through six factors. After examining all of the 
factor solutions, the factor solution with the greatest interpretability and clinical meaningfulness 
was selected, given that it met the criteria set for evaluating simple structure (i.e., size of item 
loadings, number of items on a factor). Then, each symptom cluster was evaluated to determine a 
clinically appropriate name based on the majority of the symptoms in the cluster. By conducting 
EFAs at three specific time points, we were able to compare the stability of symptom clusters 
over time. 
Differences in the Number and Types of Symptom Clusters 
To evaluate the agreement among the symptoms within the same cluster using occurrence 
and severity ratings, within and across each assessment, we used the criteria proposed by 
Kirkova and Walsh (2007). In their article, they suggested that to be in agreement with each 
other, at least 75% of the symptoms in the clusters should be present including the prominent and 
important symptom, namely the symptom with the greatest weight from the factor analyses. 
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RESULTS 
Demographic and Clinical Characteristics  
As shown in Table 1, the majority of patients were female (56.6%), white (71.8%), and 
married or partnered (64.6%). The majority of the patients (69.7%) had a current or former 
smoking history and an average of 3.2 (±1.6) comorbid conditions. 
Symptom Clusters Based on Occurrence 
As shown on Table 2, a five-factor solution was found for the T1 assessment. Factor 1 
contained six symptoms (i.e., feeling drowsy, lack of energy, problems with sexual interest or 
activity, hair loss, dizziness, pain) and was named the sickness behavior symptom cluster. Factor 
2 consisted of five symptoms (i.e., cough, difficulty breathing, shortness of breath, dry mouth, 
swelling of arms or legs) and was named the lung cancer specific symptom cluster. Factor 3 
consisted of eight symptoms (i.e., difficulty concentrating, difficulty breathing, feeling bloated, 
feeling irritable, feeling nervous, feeling sad, worrying, weight loss (loaded negatively)) and was 
named the psychological symptom cluster. Factor 4 contained nine symptoms (i.e., abdominal 
cramps, constipation, nausea, sweats, lack of appetite, weight loss, changes in skin, “I do not 
look like myself”, change in the way food tastes) and was named the epithelial/gastrointestinal 
(GI) symptom cluster. Factor 5 contained 3 symptoms (i.e., increased appetite, weight gain, lack 
of appetite (loaded negatively)) and was named the nutritional symptom cluster. 
 As shown in Table 3, for the T2 assessment, a five-factor solution was found. Factor 1 
contained 8 symptoms (i.e., abdominal cramps, constipation, difficulty concentrating, feeling 
drowsy, lack of energy, nausea, sweats, vomiting), and was named the sickness behavior 
symptom cluster. Factor 2 contained four symptoms (i.e., chest tightness, cough, difficulty 
breathing, shortness of breath) and was named the lung cancer specific symptom cluster. Factor 
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3 consisted of seven symptoms (i.e., difficulty concentrating, feeling bloated, feeling irritable, 
feeling nervous, feeling sad, problems with sexual interest or activity, worrying) and was named 
the psychological symptom cluster. Factor 4 consisted of four symptoms (i.e., increased appetite, 
lack of appetite, weight gain, weight loss) and was named nutritional symptom cluster. Factor 5 
contained four symptoms (i.e., changes in the skin, hair loss, “I do not look like myself”, mouth 
sores) and was named the epithelial symptom cluster.  
 As shown in Table 4, a five factor solution was found for the T3 assessment. Factor 1 
included four symptoms (i.e., difficulty concentrating, feeling drowsy, lack of energy, cough) 
and was named the sickness behavior symptom cluster. Factor 2 had seven symptoms (i.e., chest 
tightness, cough, difficulty breathing, shortness of breath, weight loss, pain, dizziness (loaded 
negatively)) and was named the lung cancer specific symptom cluster. Factor 3 consisted of 
thirteen symptoms (i.e., abdominal cramps, feeling drowsy, sweats, feeling bloated, lack of 
appetite, weight gain, changes in skin, hair loss, “I do not look like myself”, mouth sores, 
problems with sexual interest or activity, dizziness, change in the way food tastes) and was 
named the epithelial/GI symptom cluster. Factor 4 contained six symptoms (i.e., nausea, 
vomiting, feeling irritable, feeling nervous, feeling sad, worrying) and was name the 
psychological symptom cluster. Factor 5 had three symptoms (i.e., increased appetite, weight 
gain, lack of appetite (loaded negatively)) and was named the nutritional symptom cluster. 
Symptom Clusters Based on Severity Ratings 
 As presented in Table 5, a four factor solution was found for the T1 assessment. Factor 1 
contained eight symptoms (i.e., feeling drowsy, lack of energy, chest tightness, cough, difficulty 
breathing, shortness of breath, dizziness, pain) and was named the lung cancer specific symptom 
cluster. Factor 2 contained eight symptoms (i.e., constipation, nausea, sweats, lack of appetite, 
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weight loss, changes in skin, “I do not look like myself”, change in the way food tastes) and was 
named the epithelial/GI symptom cluster. Factor 3 consisted of seven symptoms (i.e., feeling 
bloated, feeling irritable, feeling nervous, feeling sad, worrying, difficulty sleeping, weight loss 
(loaded negatively)) and was named the psychological symptom cluster. Factor 4 contained four 
symptoms (i.e., sweats, increased appetite, weight gain, lack of appetite (loaded negatively)) and 
was named the nutritional symptom cluster. 
 As shown in Table 6, a five factor solution was found for the T2 assessment. Factor 1 
contained seventeen symptoms (i.e., abdominal cramps, constipation, difficulty concentrating, 
feeling drowsy, lack of energy, nausea, sweats, vomiting, feeling bloated, feeling nervous, 
feeling sad, problems with sexual interest or activity, worrying, dizziness, dry mouth, pain, 
swelling of legs (loaded negatively)) and was named the sickness behavior symptom cluster. 
Factor 2 consisted of five symptoms (i.e., chest tightness, cough, difficulty breathing, shortness 
of breath, swelling of arms or legs) and was named the lung cancer-specific symptom cluster. 
Factor 3 contained four symptoms (i.e., lack of appetite, weight loss, increased appetite, weight 
gain (both loaded negatively)) and was named the nutritional cluster. Factor 4 contained four 
symptoms (i.e., feeling irritable, feeling nervous, feeling sad, worrying) and was named the 
psychological symptom cluster. Factor 5 contained four symptoms (i.e., changes in skin, “I do 
not look like myself”, mouth sores, swelling of arms and legs) and was named the epithelial 
symptom cluster.  
 As presented in Table 7, a five factor solution was found for the T3 assessment. Factor 1 
contained five symptoms (i.e., difficulty concentrating, feeling irritable, feeling nervous, 
dizziness, chest tightness (loaded negatively)) and was named the sickness behavior symptom 
cluster. Factor 2 consisted of nine symptoms (i.e., difficulty concentrating, feeling drowsy, lack 
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of energy, chest tightness, cough, difficulty breathing, shortness of breath, dry mouth, pain) and 
was named the lung cancer-specific symptom cluster. Factor 3 contained thirteen symptoms (i.e., 
abdominal cramps, constipation, sweats, feeling bloated, problems with sexual interest or 
activity, lack of appetite, weight loss, changes in skin, hair loss, “I do not look like myself”, 
mouth sores, dizziness, change in the way food tastes) and was named the epithelial/GI symptom 
cluster. Factor 4 contained five symptoms (i.e., nausea, vomiting, feeling nervous, feeling sad, 
worrying) and was named the psychological symptom cluster. Factor 5 contained three 
symptoms (i.e., increased appetite, weight gain, weight loss (loaded negatively)) and was named 
the nutritional symptom cluster. 
Similarities and Differences in the Number and Types of Symptom Clusters 
 As shown in Table 8, for the occurrence dimension, the number of symptom clusters was 
five for all three time points. Across the three occurrence assessments, four of the symptom 
clusters were the same, namely; sickness behavior, lung cancer specific, psychological, and 
nutritional. While an epithelial/GI cluster occurred at T1 and T3, the epithelial symptom cluster 
was identified at T2. 
 For the severity dimension, the number of symptom clusters ranged from four to five. 
Across the three severity assessments, three of the symptom clusters were the same, namely; 
lung cancer specific, psychological, and nutritional. The sickness behavior cluster was identified 
for the T2 and T3 assessments. While the epithelial/GI cluster was found at T1 and T3, the 
epithelial cluster was only identified at T2. 
Agreement in the Types of Symptoms Within Each Symptom Cluster 
Table 8 presents a summary of the percentage agreement among the symptoms across the 
occurrence and severity dimensions and across time. For the sickness behavior cluster, the total 
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number of symptoms ranged from zero to seventeen and the percent agreement from 0.0% to 
81.0%. While no symptom was included across all of the EFAs, lack of energy and feeling 
drowsy loaded on four of the five EFAs. For the lung cancer specific cluster, the total number of 
symptoms ranged from four to nine, with percent agreement from 33.3% to 75.0%. The three 
symptoms that were included in all six EFAs were: cough, difficulty breathing, and shortness of 
breath. For the psychological cluster, the total number of symptoms ranged from four to eight 
and the percentage agreement ranged from 33.3% and 66.7%. The three symptoms that were 
included in all six EFAs were: feeling nervous, feeling sad, and worrying. For the nutritional 
cluster, the total number of symptoms ranged from three to four and the percent agreement 
ranged from 60.0% to 80.0%. The two symptoms that were found in all of the EFAs were: 
increased appetite and weight gain. The total number of symptoms in the epithelial/GI cluster 
ranged from zero to thirteen and the percent agreement ranged from 0.0% to 81.3%. The 
symptoms that were included in the four EFAs were: sweats, lack of appetite, changes in skin, “I 
do not look like myself”, and change in the way food tastes. For the epithelial cluster, the total 
number of symptoms ranged from zero to four and the percentage agreement ranged from 0.0% 
to 80.0%. Across the two EFAs, the symptoms that were common were: “I do not look like 
myself” and mouth sores.  
DISCUSSION 
This study is the first to evaluate for changes over time in the number and types of 
symptom clusters in patients with lung cancer who received CTX, by using occurrence rates and 
severity ratings. As summarized in Table 8, six clusters were identified across the two 
dimensions and the three assessments. However, only three of these clusters remained relatively 
stable across all dimensions and time (i.e., lung cancer specific, psychological, and nutritional). 
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Two of the remaining clusters varied by time, but not by dimension. For both occurrence and 
severity, the epithelial/GI cluster was identified one week before the next dose of CTX (T1) and 
two weeks after receiving CTX (T3). The epithelial cluster was found only at the T2 assessment 
for both occurrence and severity. Except for severity at T1, the sickness behavior cluster was 
found across all dimensions at T2 and T3. 
Taken together, our findings suggest that the symptom clusters remained relatively stable 
over time, regardless of the dimensions used to create the clusters. The remainder of the 
discussion will describe the variability in the specific symptoms within each cluster. Our findings 
will be compared with previous findings and the clinical implication of each symptom cluster 
will be explored.  
Lung Cancer Specific Symptom Cluster 
 A lung cancer specific cluster was identified in all six EFAs. The number of symptoms in 
this cluster ranged from four to nine. Cough, difficulty breathing, and shortness of breath were 
identified across all dimensions and time points. Of note, chest tightness was identified across all 
time points for severity and at T2 and T3 for occurrence. In three previous studies of symptom 
clusters in patients with lung cancer (Sarna & Brecht, 1997; Henoch et al., 2009; Choi, 2016), 
some type of respiratory cluster was identified. Direct comparisons of the specific symptoms 
within the lung cancer specific symptom cluster are not possible because of the different 
symptom measures used (i.e., Symptom Distress Scale (Sarna & Bretcht, 1997; Henoch et al., 
2009), M.D. Anderson Symptom Inventory (Choi et al., 2016)). 
 However, across these four studies, cough, difficulty breathing, and shortness of breath 
were the common symptoms. This consistent finding highlights the clinical importance of this 
symptom cluster in patients with lung cancer. Additional support for the clinical significance of 
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this cluster is the fact that a higher incidence of respiratory symptoms on initial presentation of 
lung cancer is associated with a poorer prognosis (Ban, et al., 2016). In addition, respiratory 
symptoms interfere with patients’ ability to perform routine activities of daily life while also 
maintaining their quality of life (Keiko et al., 2002) .  
Psychological Symptom Cluster 
 In our study a psychological cluster was identified across all of the EFAs for occurrence 
and severity. The total number of symptoms ranged from four to eight. Feeling nervous, feeling 
sad, and worrying were present in both dimensions and across all time points. In addition, feeling 
irritable was identified in five of six EFAs.  
 While none of the previous studies used the MSAS, our findings are consistent with four 
previous reports in patients with lung cancer (Sarna & Bretcht, 1997; Henoch et al., 2009; Wang 
& Fu, 2014; Choi et al., 2016). Two of these studies used the Symptom Distress Scale (SDS) 
(Sarna & Brecht, 1997; Henoch et al., 2009) and two used the MDASI (Wang & Fu, 2014; Choi 
et al., 2016) While the specific psychological symptoms on these three instruments are rather 
disparate, sad was the single common symptom across all five studies. This finding is of 
particular interest because the prevalence rates for depressive symptoms in patients with lung 
cancer ranges from 9% to 53% (Hung, et al., 2017). In addition, in a study that isolated the 
incidence of depression in the four most common cancers in the United States (Patel, Wen, & 
Aggarwal, 2018), lung cancer ranked first. Given this consistent finding, clinicians need to 
screen for psychological symptoms and recommend efficacious interventions such as cognitive 
based therapy, mindfulness training, and participation in support groups (Hulbert-Williams, 
Beatty & Dhillon, 2018). 
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Nutritional Symptom Cluster 
A nutritional cluster that included the common symptoms of increased appetite and 
weight gain was identified across both dimensions and all EFAs. Of note, lack of appetite was 
identified in five of the six EFAs and weight loss was included in three of the six EFAs. The fact 
that none of the previous studies identified a nutritional cluster in lung cancer patients may be 
related to differences in symptoms assessed. For example, in the two studies (Sarna &Brecht, 
1997; Henoch et al., 2009) that used the SDS, which assesses appetite (i.e., I have my normal 
appetite to I cannot stand the thought of food), these symptoms loaded on a gastrointestinal 
distress cluster (Sarna & Brecht, 1997) or on a pain cluster (Henoch  et al., 2009). In the two 
studies that used the MDASI which assess for lack of appetite, this symptom loaded on a general 
symptom cluster (Wang, 2008) and on a cluster named “pattern 3” that included drowsiness, 
fatigue, dry mouth, sleep disturbance, and distress (Wang, 2006). Lastly, in the study that used 
the Physical Symptom Experience tool, (Gift et al., 2004) weight loss and loss of appetite were 
part of a general symptom cluster. Weight loss and malnutrition are prevalent problems in 
patients with lung cancer and have a negative impact on an individual’s ability to tolerate 
treatment as well as survival (Kiss, 2016). Given this problem, clinicians need to assess for 
decrease in appetite and weight loss and integrate nutrition counseling.  
Epithelial/Gastrointestinal Symptom Cluster 
Our epithelial/GI cluster included symptoms associated with changes in skin, hair and 
oral mucosa that occur as a result of CTX’s action on rapidly dividing cells. While not identified 
at the T2 assessment, the common symptoms that were included in the other four EFAs were 
sweats, lack of appetite, changes in the skin, I do not look like myself, and change in the way 
food tastes. While none of the previous studies reported an epithelial/GI cluster, four studies did 
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report a GI cluster. (Sarna & Brecht, 1997; Wang, 2006; Wang 2008; Wong & Fu, 2014). Across 
these four studies the two common symptoms were nausea and vomiting. In one of the reviewed 
studies that used the SDS, (Sarna & Brecht, 1997) the appearance symptom loaded only on the 
emotional and physical suffering cluster (Sarna & Brecht, 1997). It should be noted that the 
MDASI does not assess for any symptoms related to changes in appearance, hair loss, or changes 
in skin. However, two studies that used the MSAS to assess symptom clusters in patients with 
other cancer diagnosis, a cluster that contained the symptoms I do not look like myself, changes 
in skin, and change in the way food tastes was identified (Suwisith, 2008; Yates, 2015). The 
presence of these symptoms across three heterogeneous studies suggests that they warrant 
evaluation in patients of these cancer diagnoses. 
Sickness Behavior Symptom Cluster 
We identified a sickness behavior cluster in both dimensions and across all time points, 
except for severity at T1. This cluster included the largest number of symptoms. The three most 
common symptoms that were identified were lack of energy, difficulty concentrating, and feeling 
drowsy. While this cluster was not identified in previous studies of lung cancer patients (Sarna & 
Brecht, 1997; Gift et al., 2004; Wang et al., 2008; Choi, 2016), it is a common symptom cluster 
in a number of studies of oncology patients undergoing active treatment (Sullivan et al., 2018). 
Additional studies are needed to confirm the presence of this symptom cluster in patients with 
lung cancer, and to assess if the complex treatment has a relationship to it’s existence. 
Epithelial Symptom Cluster 
Our epithelial symptom cluster, was only identified at the T2 timepoint for both 
dimensions. Similar to the epithelial/GI cluster, changes in skin, “I do not look like myself” and 
mouth sores, were the three common symptoms across the two EFAs. While it is not exactly 
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clear why this cluster was identified only at the T2 assessment, in other studies of patients with 
breast, ovarian, or heterogenous cancer diagnosis that used the MSAS, a body image related 
symptom cluster was identified that included these three symptoms (Nongluck et al., 2008; 
Huang et al., 2016; Molassiotis, 2010; Sullivan et al., 2018). Additional research is needed to 
confirm the presence of this cluster, and how it changes over time and in relation to treatments 
that are known to effect body image.  
Limitations  
Several study limitations warrant consideration. Patients were enrolled at various cycles 
during their treatment course. The number and types of symptom clusters by occurrence and 
severity may have varied if the patients were enrolled prior to the initiation of CTX. In addition, 
we were unable to use symptom distress, another important dimension of the symptom 
experience, to identify symptom clusters and compare our results using occurrence and severity 
ratings. When we evaluated the symptom distress ratings, not enough patients with each 
symptom were available to allow for accurate estimation. Lastly, five symptoms with occurrence 
rates <20% were omitted from the EFAs so their contribution to the various symptom clusters 
could not be determined. 
Conclusions 
Despite these limitations, our findings suggest that three symptom clusters (i.e., lung 
cancer specific, psychological, and nutritional) were relatively stable across both symptom 
dimensions and time. These findings warrant confirmation in independent samples. The other 
clusters that were less consistent and stable over time (i.e., sickness-behavior, epithelial/GI, 
epithelial) warrant additional research to determine their relevance in patients with lung cancer.  
Implications for Clinical Practice and Research 
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Findings from this study confirm that patients with lung cancer experience a high 
symptom burden and that three symptom clusters occur over the course of one cycle of CTX. 
Clinicians need to assess for these symptom clusters, the impact of these clusters on patients’  
functional status, and quality of life, and initiate appropriate interventions and referrals. For 
example, referrals to mental health professionals and dieticians may be warranted in patients who 
report a psychological and nutritional symptom cluster.  
 Future studies of lung cancer patients should be done to confirm the presence of all of 
these symptoms and to determine whether these clusters persist over the entire course of CTX 
and after. Additional studies are needed to identify the most effective interventions to treat these 
symptom clusters as well as identifying mechanisms for these clusters.  
 
 
 
  
 
 Table 1. Demographic and clinical characteristics of lung cancer patients receiving CTX (n = 145)a  
Characteristic N (%) 
Age in years, mean (SD) 64.0 (11.1) 
Gender  
 Female 82 (56.6) 
 Male 63 (43.4) 
Race/ethnicity  
 White 102 (71.8) 
 Asian or Pacific Islander 14 (9.9) 
 Black 14 (9.9) 
 Hispanic, Mixed, or other 12 (8.5) 
Annual household income  
 <$30,000 37 (27.6) 
 $30,000 to $69,999 31 (23.1) 
 $70,000 to $99,999 21 (15.7) 
 >$100,000 45 (33.6) 
Currently employed 36 (24.8) 
Education in years, mean (SD) 16.1 (3.4) 
Married or partnered 93 (64.6) 
Lives alone 36 (25.0) 
Smoking history  
 Current or former smoker 99 (69.7) 
 Never smoker 43 (30.3) 
BMI kg/m2, mean (SD) 25.3 (4.6) 
Patient-reported KPS score, mean (SD) 79.1 (14.6) 
SCQ score, mean (SD) 7.3 (3.9) 
No. of comorbidities, mean (SD)  3.2 (1.6) 
Comorbidities  
 Lung disease 87 (60.0) 
 Hypertension 58 (40.0) 
 Back pain 53 (36.6) 
 Depression 26 (17.9) 
 Osteoarthritis 21 (14.5) 
 Heart disease  20 (13.8) 
 Diabetes  18 (12.4) 
 Anemia or other blood disease 12 (8.3) 
 Liver disease 12 (8.3) 
 Rheumatoid arthritis 12 (8.3) 
 Ulcer or stomach disease 9 (6.2) 
 Kidney disease 1 (0.7) 
Type of lung cancer  
 Non-small cell lung cancer 126 (88.1) 
 Small cell lung cancer 17 (11.9) 
Months since cancer diagnosis, mean (SD)  15.1 (31.7)  
Months since cancer diagnosis, median (IQR) 4.2 (2.5-14.5) 
Metastatic disease at time of study 110 (76.9) 
Number of prior cancer treatments, mean (SD) 1.4 (1.4) 
Prior treatment  
 No prior treatment 54 (38.9) 
 Surgery only  17 (12.2) 
 CTX only 12 (8.6) 
 Radiation only 18 (13.0) 
 Surgery and CTX 5 (3.6) 
 Surgery and radiation 3 (2.2) 
 CTX and radiation 13 (9.4) 
 Surgery, CTX, and radiation 17 (12.2) 
CTX regimen at time of study  
 Platinum-doublet  113 (77.9) 
 Single agent CTX 29 (20.0) 
 Monoclonal antibody alone 3 (2.1) 
Mean number of MSAS symptoms (out of 38, SD) 14.3 (7.1) 
 
Abbreviations: BMI, body mass index; CTX, chemotherapy; IQR, interquartile range; kg/m2, 
kilogram per meter squared; KPS, Karnofsky Performance Status; MSAS, Memorial Symptom 
Assessment Scale; SCQ, Self-Administered Comorbidity Questionnaire; SD, standard deviation.  
aReprinted with permission from reference 45. 
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Table 2. Exploratory factory analysisa using ratings of symptom occurrence for the week prior to the next cycle of chemotherapy 
 
Symptomb Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Sickness 
Behavior 
Symptom 
Cluster 
Lung Cancer-
Specific 
Symptom 
Cluster 
Psychologica
l Symptom 
Cluster 
Epithelial/GI 
Symptom 
Cluster 
Nutritional 
Symptom 
Cluster 
Abdominal cramps 0.144 0.034 0.222 0.443 0.129 
Constipation -0.091 0.154 -0.019 0.627 0.021 
Difficulty concentrating 0.364 -0.066 0.517 -0.045 0.102 
Feeling drowsy 0.564c 0.187 0.298 -0.064 -0.170 
Lack of energy 1.021 0.081 0.025 0.004 -0.273 
Nausea 0.269 0.032 0.108 0.476 -0.091 
Sweats 0.148 0.013 0.014 0.430 0.296 
Vomiting -0.105 0.217 0.179 0.278 0.112 
Chest tightness 0.297 0.399 0.042 0.203 0.000 
Cough 0.280 0.504 0.076 0.023 0.074 
Difficulty breathing 0.060 0.772 0.407 0.006 -0.038 
Shortness of breath 0.037 0.469 0.368 0.101 0.119 
Feeling bloated -0.167 0.074 0.548 0.231 0.138 
Feeling irritable 0.086 -0.053 0.525 0.372 -0.027 
Feeling nervous 0.385 0.017 0.505 -0.053 0.243 
Feeling sad 0.148 -0.361 0.601 0.225 -0.020 
Problems with sexual interest or activity 0.467 -0.349 0.132 0.031 0.158 
Worrying -0.021 -0.297 0.925 0.088 -0.006 
Increased appetite -0.077 -0.116 0.027 0.023 1.056 
Lack of appetite -0.003 -0.206 0.049 0.814 -0.470 
Weight gain 0.046 0.037 0.070 -0.148 0.783 
Weight loss 0.380 -0.058 -0.620 0.717 0.004 
Changes in skin -0.051 0.122 0.094 0.714 -0.029 
Hair loss 0.565 0.004 -0.314 0.264 0.275 
I do not look like myself 0.061 0.042 0.175 0.543 0.003 
Mouth sores 0.206 0.027 0.310 0.136 0.295 
Dizziness 0.413 0.174 0.032 0.239 0.132 
Dry mouth 0.316 0.438 0.049 0.140 0.001 
Pain 0.456 0.226 -0.075 0.232 -0.061 
Swelling of arms or legs 0.033 0.483 -0.068 0.302 0.002 
Change in the way food tastes -0.253 0.108 -0.018 0.852 0.021 
Difficulty sleeping 0.132 -0.134 0.356 0.026 0.041 
Numbness/tingling in hands/feet 0.312 0.028 -0.125 0.355 0.166 
Total number of symptoms 6 5 8 9 3 
aExtraction method: Unweighted least squares. Rotation method: Geomin (oblique) rotation. 
bFive symptoms present in <20% of patients did not meet our criteria for inclusion in the EFA: diarrhea, difficulty swallowing, hot 
flashes, itching, problems with urination. 
cFactor loadings >0.40 are in bold.  
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Table 3. Exploratory factory analysisa using ratings of symptom occurrence for one week after the administration of chemotherapy 
 
Symptomb Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Sickness Behavior 
Symptom Cluster 
Lung Cancer-Specific 
Symptom Cluster 
Psychological 
Symptom Cluster 
Nutritional 
Symptom Cluster 
Epithelial 
Symptom Cluster 
Abdominal cramps 0.560c -0.006 0.241 -0.063 0.307 
Constipation 0.438 -0.359 -0.060 0.128 0.256 
Difficulty concentrating 0.498 0.022 0.445 -0.147 0.074 
Feeling drowsy 0.768 0.028 0.003 0.003 -0.146 
Lack of energy 0.766 0.165 0.154 0.036 0.004 
Nausea 0.869 -0.319 -0.035 0.095 -0.108 
Sweats 0.416 0.160 0.071 -0.027 0.328 
Vomiting 0.600 -0.029 0.032 0.033 -0.040 
Chest tightness 0.255 0.601 -0.012 0.089 0.098 
Cough 0.185 0.608 -0.234 -0.025 -0.002 
Difficulty breathing 0.011 0.934 0.023 0.022 -0.028 
Shortness of breath 0.070 0.900 0.080 0.140 -0.039 
Feeling bloated 0.230 -0.001 0.433 0.019 0.246 
Feeling irritable -0.163 0.175 0.803 0.036 -0.021 
Feeling nervous 0.387 0.177 0.663 0.021 -0.064 
Feeling sad 0.269 0.059 0.571 0.174 0.020 
Problems with sexual interest or activity 0.093 -0.022 0.526 -0.073 0.029 
Worrying 0.323 -0.058 0.744 -0.021 0.003 
Increased appetite 0.056 0.359 -0.002 -0.841 -0.025 
Lack of appetite 0.289 0.044 0.056 0.709 0.028 
Weight gain -0.033 0.356 -0.021 -0.867 0.214 
Weight loss 0.020 0.177 -0.128 0.526 0.385 
Changes in skin 0.030 -0.201 0.311 -0.051 0.795 
Hair loss 0.136 0.051 -0.216 0.242 0.428 
“I do not look like myself” -0.145 -0.063 0.288 0.098 0.693 
Mouth sores 0.001 0.131 -0.049 0.046 0.643 
Dizziness 0.224 -0.015 0.266 -0.153 0.226 
Dry mouth 0.398 0.202 -0.003 0.099 0.128 
Pain 0.386 0.287 -0.067 -0.020 0.125 
Swelling of arms or legs -0.182 0.285 0.041 -0.038 0.344 
Change in the way food tastes -0.079 0.180 0.302 0.205 0.288 
Difficulty sleeping 0.392 0.104 0.148 -0.117 0.011 
Numbness/tingling in hands/feet 0.274 0.279 0.002 -0.119 0.349 
Total number of symptoms 8 4 7 4 4 
aExtraction method: Unweighted least squares. Rotation method: Geomin (oblique) rotation. 
bFive symptoms present in <20% of patients did not meet our criteria for inclusion in the EFA: diarrhea, difficulty swallowing, hot 
flashes, itching, problems with urination. 
cFactor loadings >0.40 are in bold.  
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Table 4. Exploratory factory analysisa using ratings of symptom occurrence for approximately two weeks after the administration of 
chemotherapy 
 
Symptomb Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Sickness Behavior 
Symptom Cluster 
Lung Cancer-
Specific Symptom 
Cluster 
Epithelial/GI 
Symptom Cluster 
Psychological 
Symptom Cluster 
Nutritional 
Symptom Cluster 
Abdominal cramps 0.013 0.068 0.579 0.338 0.068 
Constipation -0.062 0.102 0.390 0.083 0.237 
Difficulty concentrating 0.641c 0.034 0.009 0.394 0.088 
Feeling drowsy 0.518 0.069 0.488 0.004 -0.206 
Lack of energy 0.729 -0.039 0.360 0.041 -0.099 
Nausea 0.001 0.176 0.220 0.535 -0.290 
Sweats 0.018 0.266 0.451 0.208 0.011 
Vomiting -0.089 0.246 0.078 0.624 -0.141 
Chest tightness 0.087 0.827 0.013 0.200 0.093 
Cough 0.426 0.459 -0.008 0.056 0.018 
Difficulty breathing 0.366 0.794 -0.057 0.095 -0.057 
Shortness of breath 0.367 0.631 0.105 -0.016 0.034 
Feeling bloated 0.046 -0.189 0.518 0.296 0.084 
Feeling irritable 0.117 -0.105 0.274 0.522 0.080 
Feeling nervous 0.260 -0.027 -0.047 0.735 0.022 
Feeling sad 0.150 0.074 0.023 0.771 -0.088 
Problems with sexual interest or activity 0.082 -0.344 0.561 0.180 0.051 
Worrying -0.013 -0.110 -0.008 1.001 -0.054 
Increased appetite -0.065 0.147 0.026 0.063 0.889 
Lack of appetite -0.203 -0.017 0.559 0.209 -0.420 
Weight gain -0.057 -0.022 0.407 -0.021 0.866 
Weight loss -0.259 0.451 0.285 -0.015 -0.357 
Changes in skin -0.113 0.157 0.589 0.085 -0.033 
Hair loss -0.055 -0.010 0.460 -0.066 0.049 
I do not look like myself -0.297 0.056 0.518 0.304 0.052 
Mouth sores 0.078 -0.025 0.682 -0.124 0.025 
Dizziness 0.333 -0.468 0.889 0.017 -0.026 
Dry mouth 0.395 0.237 0.368 -0.197 -0.109 
Pain 0.284 0.406 0.294 -0.045 0.123 
Swelling of arms or legs 0.107 0.181 0.234 -0.124 0.013 
Change in the way food tastes -0.365 0.078 0.624 -0.024 -0.042 
Difficulty sleeping 0.182 0.103 0.015 0.183 0.119 
Numbness/tingling in hands/feet -0.014 0.351 0.209 0.250 -0.023 
Total number of symptoms 4 7 13 6 3 
aExtraction method: Unweighted least squares. Rotation method: Geomin (oblique) rotation. 
bFive symptoms present in <20% of patients did not meet our criteria for inclusion in the EFA: diarrhea, difficulty swallowing, hot 
flashes, itching, problems with urination. 
cFactor loadings >0.40 are in bold.  
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Table 5. Exploratory factory analysisa using ratings of symptom severity for the week prior to the next cycle of chemotherapy 
administration 
 
Symptomb Factor 1 Factor 2 Factor 3 Factor 4 
Lung Cancer-Specific 
Symptom Cluster 
Epithelial/GI 
Symptom Cluster 
Psychological 
Symptom Cluster 
Nutritional 
Symptom Cluster 
Abdominal cramps 0.129 0.384 0.187 0.177 
Constipation 0.046 0.528 0.072 0.204 
Difficulty concentrating 0.281 0.126 0.383 0.122 
Feeling drowsy 0.679 -0.038 0.238 -0.165 
Lack of energy 0.621 0.215 0.039 -0.227 
Nausea 0.336 0.453 0.004 -0.022 
Sweats 0.016 0.447 -0.014 0.428 
Vomiting 0.295 0.172 -0.009 0.159 
Chest tightness 0.557 0.145 -0.066 0.133 
Cough 0.584 0.043 -0.014 0.056 
Difficulty breathing 0.835 -0.023 0.038 -0.048 
Shortness of breath 0.730 0.042 0.040 0.056 
Feeling bloated 0.045 0.249 0.404 0.238 
Feeling irritable 0.098 0.362 0.453 0.082 
Feeling nervous 0.282 -0.028 0.491 0.351 
Feeling sad -0.019 0.141 0.702 -0.069 
Problems with sexual interest or activity 0.097 -0.021 0.262 0.265 
Worrying -0.047 0.073 0.911 -0.006 
Increased appetite -0.347 0.043 0.044 0.984 
Lack of appetite -0.012 0.815 0.109 -0.508 
Weight gain -0.171 -0.075 0.019 0.879 
Weight loss 0.038 0.740 -0.443 0.028 
Changes in skin -0.042 0.790 0.048 -0.039 
Hair loss 0.177 0.340 -0.196 0.263 
I do not look like myself -0.018 0.597 0.190 0.017 
Mouth sores 0.056 0.224 0.252 0.399 
Dizziness 0.403 0.261 0.029 0.187 
Dry mouth 0.354 0.336 0.052 0.024 
Pain 0.454 0.280 -0.076 0.036 
Swelling of arms or legs 0.281 0.317 -0.228 -0.029 
Change in the way food tastes -0.160 0.894 -0.076 -0.064 
Difficulty sleeping 0.189 -0.085 0.470 -0.011 
Numbness/tingling in hands/feet 0.114 0.374 -0.021 0.233 
Total number of symptoms 8 8 7 4 
aExtraction method: Unweighted least squares. Rotation method: Geomin (oblique) rotation. 
bFive symptoms present in <20% of patients did not meet our criteria for inclusion in the EFA: diarrhea, difficulty swallowing, hot 
flashes, itching, problems with urination. 
cFactor loadings >0.40 are in bold.  
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Table 6. Exploratory factory analysisa using ratings of symptom severity for one week after the administration of chemotherapy 
 
Symptomb Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Sickness Behavior 
Symptom Cluster 
Lung Cancer-Specific 
Symptom Cluster 
Nutritional 
Symptom Cluster 
Psychological 
Symptom Cluster 
Epithelial Symptom 
Cluster 
Abdominal cramps 0.572c 0.013 -0.102 0.037 0.226 
Constipation 0.441 -0.230 0.072 -0.049 0.183 
Difficulty concentrating 0.509 0.010 0.010 0.307 0.125 
Feeling drowsy 0.667 0.117 0.139 -0.027 -0.081 
Lack of energy 0.775 0.135 0.197 0.010 0.007 
Nausea 0.709 -0.189 0.193 -0.059 -0.068 
Sweats 0.629 0.130 -0.066 -0.135 0.159 
Vomiting 0.543 0.033 -0.079 -0.044 -0.092 
Chest tightness 0.254 0.643 -0.018 -0.023 0.032 
Cough 0.114 0.670 -0.109 -0.017 -0.212 
Difficulty breathing -0.083 0.948 0.004 0.203 0.032 
Shortness of breath 0.128 0.806 0.044 0.217 -0.026 
Feeling bloated 0.430 -0.110 -0.090 0.069 0.358 
Feeling irritable 0.004 0.156 -0.008 0.674 0.225 
Feeling nervous 0.429 0.234 -0.008 0.469 -0.036 
Feeling sad 0.408 0.047 0.141 0.653 0.006 
Problems with sexual interest or activity 0.555 -0.267 -0.169 0.108 0.012 
Worrying 0.482 -0.079 -0.025 0.668 0.069 
Increased appetite 0.194 0.088 -0.845 0.012 0.000 
Lack of appetite 0.323 0.076 0.723 0.025 0.119 
Weight gain 0.027 0.205 -0.843 -0.102 0.211 
Weight loss 0.054 0.349 0.524 -0.158 0.262 
Changes in skin -0.004 -0.078 0.032 0.026 0.889 
Hair loss 0.137 0.157 0.197 -0.244 0.238 
“I do not look like myself” -0.046 -0.026 0.107 0.129 0.752 
Mouth sores 0.079 0.125 -0.032 -0.307 0.535 
Dizziness 0.489 0.038 -0.190 0.039 0.133 
Dry mouth 0.407 0.227 0.068 -0.031 0.118 
Pain 0.432 0.219 0.103 0.171 -0.082 
Swelling of arms or legs -0.453 0.438 -0.003 0.005 0.448 
Change in the way food tastes 0.190 0.012 0.242 0.104 0.339 
Difficulty sleeping 0.313 0.178 -0.065 0.229 0.164 
Numbness/tingling in hands/feet 0.071 0.284 -0.137 0.111 0.296 
Total number of symptoms 17 5 4 4 4 
aExtraction method: Unweighted least squares. Rotation method: Geomin (oblique) rotation. 
bFive symptoms present in <20% of patients did not meet our criteria for inclusion in the EFA: diarrhea, difficulty swallowing, hot 
flashes, itching, problems with urination. 
cFactor loadings >0.40 are in bold.  
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Table 7. Exploratory factory analysisa using ratings of symptom severity for approximately two weeks after the administration of 
chemotherapy 
 
Symptomb Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Sickness Behavior 
Symptom Cluster 
Lung Cancer-Specific 
Symptom Cluster 
Epithelial/GI 
Symptom Cluster 
Psychological 
Symptom Cluster 
Nutritional 
Symptom Cluster 
Abdominal cramps 0.238 0.138 0.541 0.154 0.015 
Constipation 0.048 -0.021 0.543 0.046 0.236 
Difficulty concentrating 0.629 0.418 -0.091 0.043 0.007 
Feeling drowsy 0.223 0.415 0.214 0.120 -0.135 
Lack of energy 0.292 0.586 0.074 -0.056 -0.162 
Nausea 0.014 0.234 0.196 0.525 -0.120 
Sweats -0.043 0.285 0.455 0.212 0.032 
Vomiting 0.005 0.155 -0.028 0.771 0.027 
Chest tightness -0.418 0.745 -0.004 0.233 0.136 
Cough -0.126 0.595 -0.004 0.134 -0.157 
Difficulty breathing 0.078 0.898 -0.094 -0.012 -0.042 
Shortness of breath 0.055 0.764 0.094 -0.107 0.111 
Feeling bloated 0.328 0.039 0.467 0.096 0.225 
Feeling irritable 0.452 0.013 0.366 0.173 -0.004 
Feeling nervous 0.425 0.026 -0.007 0.566 0.026 
Feeling sad 0.328 0.017 0.077 0.701 -0.159 
Problems with sexual interest or activity 0.355 -0.104 0.483 0.010 0.073 
Worrying 0.322 -0.049 0.109 0.733 -0.019 
Increased appetite -0.029 0.054 0.032 0.015 0.855 
Lack of appetite 0.050 0.016 0.661 0.046 -0.370 
Weight gain 0.013 0.022 0.327 -0.036 0.854 
Weight loss -0.333 0.236 0.617 -0.007 -0.446 
Changes in skin 0.001 0.059 0.662 0.044 -0.038 
Hair loss 0.006 0.089 0.419 0.012 -0.050 
I do not look like myself -0.046 -0.125 0.604 0.339 0.111 
Mouth sores 0.193 -0.024 0.736 -0.278 0.008 
Dizziness 0.434 0.094 0.562 -0.097 0.028 
Dry mouth 0.052 0.448 0.309 -0.149 -0.084 
Pain -0.079 0.530 0.175 0.067 0.052 
Swelling of arms or legs -0.056 0.083 0.202 0.052 -0.053 
Change in the way food tastes -0.190 -0.095 0.831 0.018 -0.069 
Difficulty sleeping 0.279 0.210 -0.038 0.299 0.053 
Numbness/tingling in hands/feet -0.024 0.296 0.245 0.093 0.093 
Total number of symptoms 5 9 13 5 3 
aExtraction method: Unweighted least squares. Rotation method: Geomin (oblique) rotation. 
bFive symptoms present in <20% of patients did not meet our criteria for inclusion in the EFA: diarrhea, difficulty swallowing, hot 
flashes, itching, problems with urination. 
cFactor loadings >0.40 are in bold.  
    
Table 8. Summary of symptom clusters over time using occurrence rates and severity ratings  
 
Symptom Cluster Symptoms Within the Cluster Occurrence Severity 
T1 T2 T3 T1 T2 T3 
Sickness Behavior 
Symptom Cluster 
Lack of energy ● ● ● 
N 
O 
T 
 
I 
D 
E 
N 
T 
I 
F 
I 
E 
D 
●  
Problems with sexual interest or activity ●   ●  
Hair loss ●     
Dizziness ●   ● ● 
Dry mouth    ●  
Abdominal cramps  ●  ●  
Constipation  ●  ●  
Difficult concentrating  ● ● ● ● 
Nausea  ●  ●  
Sweats  ●  ●  
Vomiting  ●  ●  
Cough   ●   
Feeling bloated    ●  
Feeling drowsy ● ● ● ●  
Feeling irritable     ● 
Feeling nervous    ● ● 
Feeling sad    ●  
Worrying    ●  
Pain ●   ●  
Swelling of arms or legs    ●  
Chest tightness     ● 
Percent agreement 28.6% 38.1% 19.0% 0.0% 81.0% 23.8% 
Lung Cancer Specific 
Symptom Cluster 
Cough ● ● ● ● ● ● 
Difficulty breathing ● ● ● ● ● ● 
Shortness of breath ● ● ● ● ● ● 
Dry mouth ●    ● ● 
Swelling of arms or legs ●      
Chest tightness  ● ● ● ● ● 
Weight loss   ●    
Dizziness   ● ●   
Pain   ● ●  ● 
Difficulty concentrating      ● 
Feeling drowsy    ●  ● 
Lack of energy    ●  ● 
Percent agreement 41.6% 33.3% 58.3% 66.7% 41.7% 75.0% 
Psychological Symptom 
Cluster 
Difficulty concentrating ● ●     
Difficulty breathing ●      
Feeling bloated ● ●  ●   
Feeling irritable ● ● ● ● ●  
Feeling nervous ● ● ● ● ● ● 
Feeling sad ● ● ● ● ● ● 
Worrying ● ● ● ● ● ● 
Weight loss ●   ●   
Problems with sexual interest or activity  ●     
    
Vomiting   ●   ● 
Nausea   ●   ● 
Difficulty sleeping    ●   
Percent agreement 66.7% 58.3% 50.0% 58.3% 33.3% 41.7% 
Nutritional Symptom 
Cluster 
Increased appetite ● ● ● ● ● ● 
Sweats    ●   
Lack of appetite ● ● ● ● ●  
Weight gain ● ● ● ● ● ● 
Weight loss  ●   ● ● 
Percent agreement 60.0% 80.0% 60.0% 80.0% 80.0% 60.0% 
Epithelial/Gastrointestinal 
Symptom Cluster 
Abdominal cramps ● 
N 
O 
T 
 
I 
D 
E 
N 
T 
I 
F 
I 
E 
D 
●  
N 
O 
T 
 
I 
D 
E 
N 
T 
I 
F 
I 
E 
D 
● 
Constipation ●  ● ● 
Nausea ●  ●  
Sweats ● ● ● ● 
Lack of appetite ● ● ● ● 
Weight loss ●  ● ● 
Changes in skin ● ● ● ● 
I do not look like myself ● ● ● ● 
Change in the way food tastes ● ● ● ● 
Mouth sores  ●  ● 
Hair loss  ●  ● 
Feeling drowsy  ●   
Feeling bloated  ●  ● 
Weight gain  ●   
Dizziness  ●  ● 
Problems with sexual interest or activity  ●  ● 
Percent agreement 56.3% 0.0% 81.3% 50.0% 0.0% 81.3% 
Epithelial Symptom 
Cluster 
Changes in skin 
NOT 
IDENTIFIED 
 
● 
NOT 
IDENTIFIED 
 
NOT 
IDENTIFIED 
 
● 
NOT 
IDENTIFIED 
 
Hair loss ●  
“I do not look like myself” ● ● 
Mouth sores ● ● 
Swelling of arms and legs  ● 
Percent agreement 0.0% 80.0% 0.0% 0.0% 80.0% 0.0% 
Total number of symptom clusters 5 5 5 4 5 5 
 
 References 
 
 
1. Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. J Natl Cancer Inst 
Monogr 2004:76-8. 
2. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis 
and clinical implications for cancer nursing. Cancer Nurs 2005;28:270-82; quiz 283-4. 
3. Given B, Given C, Azzouz F, Stommel M. Physical functioning of elderly cancer patients 
prior to diagnosis and following initial treatment. Nurs Res 2001;50:222-32. 
4. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional 
status of patients with cancer. Oncol Nurs Forum 2001;28:465-70. 
5. Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters on 
functional status and quality of life in women with breast cancer. Eur J Oncol Nurs 
2010;14:101-10. 
6. Hwang KH, Cho OH, Yoo YS. Symptom clusters of ovarian cancer patients undergoing 
chemotherapy, and their emotional status and quality of life. Eur J Oncol Nurs 2015. 
7. Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on 
functional status and quality of life of elderly patients with cancer. Crit Rev Oncol 
Hematol 2011;78:127-37. 
8. Dong ST, Costa DS, Butow PN, et al. Symptom Clusters in Advanced Cancer Patients: 
An Empirical Comparison of Statistical Methods and the Impact on Quality of Life. J 
Pain Symptom Manage 2016;51:88-98. 
9. Fox SW, Lyon DE. Symptom clusters and quality of life in survivors of lung cancer. 
Oncol Nurs Forum 2006;33:931-6. 
 10. Henoch I, Lovgren M. The influence of symptom clusters and the most distressing 
concerns regarding quality of life among patients with inoperable lung cancer. Eur J 
Oncol Nurs 2014;18:236-41. 
11. Lin S, Chen Y, Yang L, Zhou J. Pain, fatigue, disturbed sleep and distress comprised a 
symptom cluster that related to quality of life and functional status of lung cancer surgery 
patients. J Clin Nurs 2013;22:1281-90. 
12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 
13. Silvoniemi M, Vasankari T, Loyttyniemi E, Valtonen M, Salminen E. Symptom 
Assessment for Patients with Non-small Cell Lung Cancer Scheduled for Chemotherapy. 
Anticancer Res 2016;36:4123-8. 
14. Barbera L, Seow H, Howell D, et al. Symptom burden and performance status in a 
population-based cohort of ambulatory cancer patients. Cancer 2010;116:5767-76. 
15. Sarna L, Brecht M-L. Dimensions of symptom distress in women with advanced lung 
cancer: A factor analysis. Heart & Lung: The Journal of Acute and Critical Care 
1997;26:23-30. 
16. Gift AG, Jablonski A, Stommel M, Given CW. Symptom clusters in elderly patients with 
lung cancer. Oncol Nurs Forum 2004;31:202-12. 
17. Wang D, Fu J. Symptom clusters and quality of life in China patients with lung cancer 
undergoing chemotherapy. Afr Health Sci 2014;14:49-55. 
18. Wang XS, Fairclough DL, Liao Z, et al. Longitudinal Study of the Relationship Between 
Chemoradiation Therapy for Non–Small-Cell Lung Cancer and Patient Symptoms. 
Journal of Clinical Oncology 2006;24:4485-4491. 
 19. Wang SY, Tsai CM, Chen BC, Lin CH, Lin CC. Symptom clusters and relationships to 
symptom interference with daily life in Taiwanese lung cancer patients. J Pain Symptom 
Manage 2008;35:258-66. 
20. Miaskowski C. Future Directions in Symptom Cluster Research. Semin Oncol Nurs 
2016;32:405-415. 
21. Miaskowski C, Barsevick A, Berger A, et al. Advancing symptom science through 
symptom cluster research: Expert panel proceedings and recommendations. Journal of the 
National Cancer Institute 2016. 
22. Kim E, Jahan T, Aouizerat BE, et al. Differences in symptom clusters identified using 
occurrence rates versus symptom severity ratings in patients at the end of radiation 
therapy. Cancer Nurs 2009;32:429-36. 
23. Baggott C, Cooper BA, Marina N, Matthay KK, Miaskowski C. Symptom cluster 
analyses based on symptom occurrence and severity ratings among pediatric oncology 
patients during myelosuppressive chemotherapy. Cancer Nurs 2012;35:19-28. 
24. Suwisith N, Hanucharururnkul S, Dodd M, et al. Symptom clusters and functional status 
of women with breast cancer. Thai Journal of Nursing Research 2008;12:153-165. 
25. Kirkova J, Walsh D. Cancer symptom clusters--a dynamic construct. Support Care 
Cancer 2007;15:1011-3. 
26. Miaskowski C, Cooper BA, Melisko M, et al. Disease and treatment characteristics do 
not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. 
Cancer 2014;120:2371-8. 
 27. Miaskowski C, Cooper BA, Aouizerat B, et al. The symptom phenotype of oncology 
outpatients remains relatively stable from prior to through 1 week following 
chemotherapy. Eur J Cancer Care (Engl) 2016. 
28. Karnofsky D, Abelmann WH, Craver LV, Burchenal JH. The use of nitrogen mustards in 
the palliative treatment of carcinoma. Cancer 1948;1:634-56. 
29. Ando M, Ando Y, Hasegawa Y, et al. Prognostic value of performance status assessed by 
patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J 
Cancer 2001;85:1634-9. 
30. Schnadig ID, Fromme EK, Loprinzi CL, et al. Patient-physician disagreement regarding 
performance status is associated with worse survivorship in patients with advanced 
cancer. Cancer 2008;113:2205-14. 
31. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered 
Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health 
services research. Arthritis Rheum 2003;49:156-63. 
32. Brunner F, Bachmann LM, Weber U, et al. Complex regional pain syndrome 1--the 
Swiss cohort study. BMC Musculoskelet Disord 2008;9:92. 
33. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale 
- an Instrument for the Evaluation of Symptom Prevalence, Characteristics and Distress. 
European Journal of Cancer 1994;30a:1326-1336. 
34. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and 
distress in a cancer population. Qual Life Res 1994;3:183-189. 
35. Muthen LK, Muthen BO. Mplus User's Guide (7th ed.), 7th ed. Los Angeles, CA: 
Muthen & Muthen, 1998-2015. 
 36. Babor TF, de la Fuente JR, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders 
Identification Test: Guidelines for Use in Primary Care. In: Geneva, Switzerland: World 
Health Organization, 1992. 
37. Miaskowski C, Dodd M, Lee K. Symptom clusters: the new frontier in symptom 
management research. J Natl Cancer Inst Monogr 2004:17-21. 
38. Berner MM, Kriston L, Bentele M, Harter M. The alcohol use disorders identification test 
for detecting at-risk drinking: a systematic review and meta-analysis. J Stud Alcohol 
Drugs 2007;68:461-73. 
39. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and 
distress in a cancer population. Qual Life Res 1994;3:183-9. 
40. SPSS. IBM SPSS for Windows (Version 23), Armonk, NY: SPSS, Inc., 2015. 
41. StataCorp. Stata Statistical Software: Release 14, College Station, Texas: Stata 
Corporation, 2015. 
42. Muthen BO. Dichotomous Factor-Analysis of Symptom Data. Sociological Methods & 
Research 1989;18:19-65. 
43. Miaskowski C, Aouizerat BE, Dodd M, Cooper B. Conceptual issues in symptom clusters 
research and their implications for quality-of-life assessment in patients with cancer. J 
Natl Cancer Inst Monogr 2007:39-46. 
44. Brown TA. The common factor model and exploratory factor analysis, 2nd ed. London: 
The Guilford Press, 2015. 
45. Wong ML, Paul SM, Cooper BA, et al. Predictors of the multidimensional symptom 
experience of lung cancer patients receiving chemotherapy. Support Care Cancer (In 
press). 
 46. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to 
sickness and depression: when the immune system subjugates the brain. Nat Rev 
Neurosci 2008;9:46-56. 
47. McCusker RH, Kelley KW. Immune-neural connections: how the immune system's 
response to infectious agents influences behavior. J Exp Biol 2013;216:84-98. 
48. Chen E, Nguyen J, Cramarossa G, et al. Symptom clusters in patients with lung cancer: a 
literature review. Expert Rev Pharmacoecon Outcomes Res 2011;11:433-9. 
49. Henoch I, Ploner A, Tishelman C. Increasing stringency in symptom cluster research: a 
methodological exploration of symptom clusters in patients with inoperable lung cancer. 
Oncol Nurs Forum 2009;36:E282-92. 
50. Yorke J, Lloyd-Williams M, Smith J, et al. Management of the respiratory distress 
symptom cluster in lung cancer: a randomised controlled feasibility trial. Support Care 
Cancer 2015. 
51. Dong ST, Butow PN, Costa DS, Lovell MR, Agar M. Symptom clusters in patients with 
advanced cancer: a systematic review of observational studies. J Pain Symptom Manage 
2014;48:411-50. 
52. . Fan G, Filipczak L, Chow E. Symptom clusters in cancer patients: a review of the 
literature. Curr Oncol 2007;14:173-9. 
53. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. 
Brain Behav Immun 2007;21:153-60. 
54. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer 
patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-46. 
 55. 55. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 
1978;1:373-8. 
56. 56. Huang J, Gu L, Zhang L, et al. Symptom Clusters in Ovarian Cancer Patients With 
Chemotherapy After Surgery: A Longitudinal Survey. Cancer Nurs 2016;39:106-16. 
57. 57. Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first 
year after diagnosis with cancer. J Pain Symptom Manage 2010;39:847-58. 
 
Scanned with CamScanner
